Skip to product information
1 of 1

CONQUER LABS

PT-141 | SEX DRIVE

PT-141 | SEX DRIVE

Regular price $77.00 USD
Regular price $90.00 USD Sale price $77.00 USD
Sale Sold out

20  mg of  PT-141 per bottle ,100 MCG per spray 

PT-141, also known as Bremelanotide, is a synthetic peptide that acts as a melanocortin receptor agonist. It is primarily used for its potential effects on sexual dysfunction and arousal. However, it's important to note that the use of PT-141 for non-medical purposes may be subject to regulations and restrictions in certain jurisdictions.

The main uses and potential benefits of PT-141 include:

  1. Treatment of sexual dysfunction: PT-141 has been investigated as a potential treatment for sexual disorders, such as erectile dysfunction (ED) in men and hypoactive sexual desire disorder (HSDD) in both men and women. It is believed to work by activating the melanocortin receptors in the brain, leading to increased sexual arousal and desire.

  2. Improved sexual response: PT-141 has the potential to enhance sexual response by increasing genital blood flow and sensitivity. It may promote the relaxation of smooth muscles in the erectile tissues, leading to improved erectile function and sexual satisfaction.

  3. Potential for female sexual enhancement: PT-141 has shown promise in addressing female sexual dysfunction and enhancing sexual desire and arousal in women. It may help increase libido and improve overall sexual experience.

When it comes to dosages of PT-141, it is essential to consult with a medical professional or a qualified healthcare provider. Dosages can vary depending on factors such as the individual's medical history, current medications, and desired outcomes. For the treatment of erectile dysfunction (ED) in men, a common starting dosage of PT-141 is around 1.25 mg. This initial dose can be adjusted based on individual response and tolerability, with some individuals potentially requiring higher or lower doses. It is important to follow the dosage recommendations provided by your healthcare provider.

For the treatment of hypoactive sexual desire disorder (HSDD) in women, the recommended starting dosage is typically around 1.75 mg. As with the dosage for ED, this initial dose may be adjusted based on individual response and tolerability.


TERMS: All items offered by CONQUER RESEARCH are explicitly designated for research and laboratory purposes exclusively. These products are not intended, formulated, or approved for human consumption, medical, veterinary, or household applications. It is strictly prohibited to utilize any items acquired from CONQUER RESEARCH for purposes other than research and laboratory use. This prohibition encompasses, but is not limited to, any form of consumption, medical treatment, veterinary use, or household application. CONQUER RESEARCH upholds a no-sell list of individuals and entities discovered violating our intended use policy. Those found using our products improperly will be included in this list, preventing future purchases from CONQUER RESEARCH.

View full details